Lung tumour markers in oncology practice: A study of TPA and CA 125

British Journal of Cancer

Volumn 87, Issue 10, 2002, Pages 1112-1118

  Buccheri, G ^a   Ferrigno, D ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

CA 125; Lung neoplasm; Neoplasm staging; Prognosis; Tissue polypeptide antigen; Tumour markers

Indexed keywords

CA 125 ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTHROPOMETRY; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

CA-125 ANTIGEN; HUMANS; LUNG NEOPLASMS; PROGNOSIS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0037021251     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600577     Document Type: Article

References (33)

1. Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T (2001) Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res 21: 3085-3092
2. Bast RC, Feeney M, Zazarus H (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331-1337
3. Bast RC, Klul TLSJE (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883-887
4. Bjorklund B (1953) Serological analysis of human cancer antigen. In Proceedings: VI Internat.Congres.Microbiol, p 344 Rome
5. Bjorklund B (1978) Tissue polypeptide antigen (TPA): Biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. In Laboratory Testing for Cancer, Schonfeld H (ed) pp 16-31. Basel: Karger
6. Bjorklund B (1980) On the nature and dinical use of tissue polypeptide antigen (TPA). Tumor Diagnostik 1: 9-20
7. Buccheri G (1999) Tumor Markers: Clinical Meaning and Use. In Lung Tumors, Brambilla C, Brambilla E (eds) pp 435-452. New York: Marcel Dekker, Inc
8. Buccheri G, Ferrigno D (1988) Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer. Chest 93: 565-569
9. Buccheri G, Ferrigno D (1992) Prognostic value of the tissue polyptide antigen in lung cancer. Chest 101: 1287-1292
10. Buccheri G, Ferrigno D (1995a) Monitoring lung cancer with tissue polyptide antigen: An ancillary, profitable serum test to evaluate treatment response and posttreatment disease status. Lung Cancer 13: 155-168
11. Buccheri G, Ferrigno D (1995b) The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: Diagnostic yield and comparison with conventional staging methods. Chest 107: 471-476
12. Buccheri G, Ferrigno D (2001a) Lung tumor markers of cytokeratin origin: An overview. Lung Cancer 34(Suppl 2): S65-S69
13. Buccheri G, Ferrigno D (2001b) Serum biomarkers facilitate the recognition of early-stage cancer and may guide the selection of surgical candidates: A study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. J Thorac Cardiovasc Surg 122: 891-899
14. Buccheri G, Ferrigno D, Vola F (1993) Carcinoembryonic antigen (CEA), tissue polyptide antigen (TPA), and other prognostic indicators in the squamous cell carcinoma of the lung. Lung Cancer 10: 21-33
15. Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A (1987) Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 60: 42-50
16. Buccheri GF, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola F (1986) Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer 57: 2389-2396
17. Coombes RC, Powels TJ (1982) Tumour markers in the management of human cancer. In Topical Reviews in Radiotherapy and Oncology, Deeley TJ (ed) p 39. Bristol: Wright PGS
18. Cox DR (1972) Regression models and life tables. JR Stat Soc 34: 187-220
19. Diez M, Cerdan FJ, Ortega MD, Torres A, Picardo A, Balibrea JL (1991) Evaluation of serum CA 125 as a tumor marker in non-small cell lung cancer. Cancer 67: 150-154
20. Diez M, Torres A, Maestro ML, Ortega MD, Gomez A, Pollan M, Lopez JA, Picardo A, Hernando F, Balibrea JL (1996) Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer 73: 1248-1254
21. Diez M, Torres A, Pollán M, Gomez A, Ortega D, Maestro ML, Granell J, Balibrea JL (1994) Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer. Cancer 73: 1368-1376
22. Ferrigno D, Buccheri G, Rendine S (1989) The prognostic value of CEA and TPA in the initial evaluation of lung cancer: Results of a multivariate analysis of 312 patients. In Lung Cancer: Advanced Concepts and Present Status, Motta G (ed) pp 179-188. Genova: IASLG
23. Hanley JA, McNeil BJ (1982) The meaning and use of the area under receiving operating characteristic (ROC) curve. Radiology 43: 29-36
24. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB (1983) Tissue distribution of a coelomic-epithelium-relayted antigen recognized by the monoclonal antibody OC125. Int J Pathol 2: 275-279
25. Kaplan EL, Meier F (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 58: 457-481
26. Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M, Iio A (1990) Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer 62: 626-628
27. Molina R, Agusti C, Mañe JM, Filella X, Jo J, Joseph J, Giménez N, Estapé J, Ballesta AM (1994) CYFRA 21-1 in lung cancer: Comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 9: 96-101
28. McNeil BJ, Keeler E, Adelstein SJ (1975) Primer on certain element of decision making. N Engl J Med 293: 211-215
29. Pamies RJ, Crawford DR (1996) Tumor markers - An update. Med Clin North Am 80: 185-199
30. Peto R, Pike MC, Armitage P (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II Analysis and examples. Br J Cancer 35: 1-39
31. Picardo AL, Torres AJ, Maestro M, Ortega D, Garcia-Asenjo JA, Mugüerza JM, Hernando F, Diez M, Balibrea JL (1994) Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer. Cancer 73: 2305-2311
32. Siegel S (1956) Nonparametric Statistics for the Behavioural Sciences. New York: MacGraw Hill
33. World Health Organization (1991) International Histological Classification of Tumours. Berlin: Springer-Verag